An analysis of recent mergers and acquisitions in the pharma sector.
During the first half of 2023, there has been intense market activity, with pharma and biotech companies spending more than $87 billion as they seek to expand growth through strategic acquisitions.
Table 1: M&A activity in the first half of 2023 ($ billions)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze